Microfluidic processor allows rapid HER2 immunohistochemistry of breast carcinomas and significantly reduces ambiguous (2+) read-outs

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 14, 2013, Pages 5363-5368

  Ciftlik, Ata Tuna ^a   Lehr, Hans Anton ^b,c   Gijs, Martin A M ^a  

^a EPFL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Institut für Pathologie im Medizin Campus Bodensee ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SILICON; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICROFLUIDICS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SECTION;

BREAST NEOPLASMS; FEMALE; FLUORESCENCE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MICROFLUIDIC ANALYTICAL TECHNIQUES; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84875850620     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1211273110     Document Type: Article

References (37)

1. Cattoretti G, et al. (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168(4):357-363.
2. Slamon DJ, et al. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177-182.
3. Baak JP, Chin D, van Diest PJ, Ortiz R, Matze-Cok P, Bacus SS (1991) Comparative longterm prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. Lab Invest 64(2):215-223.
4. Vogel CL, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3): 719-726.
5. Slamon DJ, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11): 783-792.
6. Wolff AC, et al.; American Society of Clinical Oncology; College of American Pathologists (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118-145.
7. Moelans CB, de Weger RA, Van der Wall E, van Diest PJ (2011) Current technologies for HER2 testing in breast cancer. Crit Rev Oncol Hematol 80(3):380-392.
8. Pauletti G, et al. (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18(21):3651-3664.
9. Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5(1):63-69.
10. Kostopoulou E, et al. (2007) Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR. Breast 16(6): 615-624.
11. Bussolati G, Leonardo E (2008) Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol 61(11):1184-1192.
12. Marchiò C, Dowsett M, Reis-Filho JS (2011) Revisiting the technical validation of tumour biomarker assays: How to open a Pandora's box. BMC Med 9(1):41.
13. Yaziji H, Barry T (2006) Diagnostic immunohistochemistry: What can go wrong? Adv Anat Pathol 13(5):238-246.
14. Fernández-Moreira V, et al. (2010) Bioconjugated lanthanide luminescent helicates as multilabels for lab-on-a-chip detection of cancer biomarkers. Analyst (Lond) 135(1): 42-52.
15. Ciftlik AT, et al. (2010) Fast immunohistochemical biomarker detection device for cancer tissue slices. Proceedings of 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences, Groningen, Netherlands (Chemical and Biological Microsystems Society, San Diego), pp 699-701.
16. Kim MS, et al. (2010) Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform. PLoS ONE 5(5):e10441.
17. Kim MS, Kwon S, Kim T, Lee ES, Park J-K (2011) Quantitative proteomic profiling of breast cancers using a multiplexed microfluidic platform for immunohistochemistry and immunocytochemistry. Biomaterials 32(5):1396-1403.
18. Sivagnanam V, Song B, Vandevyver C, Gijs MAM (2009) On-chip immunoassay using electrostatic assembly of streptavidin-coated bead micropatterns. Anal Chem 81(15): 6509-6515.
19. Stenberg M, Nygren H (1988) Kinetics of antigen-antibody reactions at solid-liquid interfaces. J Immunol Methods 113(1):3-15.
20. Nygren H, Werthen M, StenbergM (1987) Kinetics of antibody binding to solid-phaseimmobilised antigen. Effect of diffusion rate limitation and steric interaction. J Immunol Methods 101(1):63-71.
21. Stenberg M, Werthén M, Theander S, Nygren H (1988) A diffusion limited reaction theory for a microtiter plate assay. J Immunol Methods 112(1):23-29.
22. Vijayendran RA, Ligler FS, Leckband DE (1999) A computational reaction-diffusion model for the analysis of transport-limited kinetics. Anal Chem 71(23):5405-5412.
23. Zimmermann M, Delamarche E, Wolf M, Hunziker P (2005) Modeling and optimization of high-sensitivity, low-volume microfluidic-based surface immunoassays. Biomed Microdevices 7(2):99-110.
24. Ciftlik AT, Gijs MAM (2012) Parylene to silicon nitride bonding for post-integration of high pressure microfluidics to CMOS devices. Lab Chip 12(2):396-400.
25. Anthony A, Colurso GJ, Bocan TM, Doebler JA (1984) Interferometric analysis of intrasection and intersection thickness variability associated with cryostat microtomy. Histochem J 16(1):61-70.
26. Gustavson MD, et al. (2009) Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch Pathol Lab Med 133(9):1413-1419.
27. Lee AHS, Key HP, Bell JA, Hodi Z, Ellis IO (2011) Breast carcinomas with borderline (2+) HER2 immunohistochemistry: Percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification. J Clin Pathol 64(6):490-492.
28. Sadana A, Ram AB (1994) Fractal analysis of antigen-antibody binding kinetics: Biosensor applications. Biotechnol Prog 10(3):291-298.
29. Kusnezow W, Syagailo YV, Goychuk I, Hoheisel JD, Jr., Wild DG (2006) Antibody microarrays: The crucial impact of mass transport on assay kinetics and sensitivity. Expert Rev Mol Diagn 6(1):111-124.
30. Nygren H (1994) Kinetics of antibody binding to surface-immobilized antigen. Analysis of data and an empiric model. Biophys Chem 52(1):45-50.
31. Kusnezow W, et al. (2006) Kinetics of antigen binding to antibody microspots: Strong limitation by mass transport to the surface. Proteomics 6(3):794-803.
32. Yanagisawa N, Dutta D (2011) Kinetic ELISA in microfluidic channels. Biosensors 1(2): 58-69.
33. Nygren H, Stenberg M (1989) Immunochemistry at interfaces. Immunology 66(3): 312-327.
34. Nygren H (1995) Real-time recording of antigen-antibody reactions at surfaces: Interpretation of data and a statistical model. Colloids Surf B Biointerfaces 4(4): 243-250.
35. Caelen I, et al. (2000) Formation of gradients of proteins on surfaces with microfluidic networks. Langmuir 16(24):9125-9130.
36. Towne V, Will M, Oswald B, Zhao Q (2004) Complexities in horseradish peroxidasecatalyzed oxidation of dihydroxyphenoxazine derivatives: Appropriate ranges for pH values and hydrogen peroxide concentrations in quantitative analysis. Anal Biochem 334(2):290-296.
37. Press MF, et al. (2005) Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11(18):6598-6607.